CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 119 enrolled
Drug / intervention
Corticosteroid +2 moredrug
Likely dose
Corticosteroid 1 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06236178
NCT06236178N/ACompleted

Comparing Autologous Blood, Corticosteroid, and Their Combined Injection for Treating Lateral Epicondylitis: A Randomized Clinical Trial

Istanbul Training and Research Hospital·interventional·Posted Feb 1, 2024·Updated Feb 1, 2024

In Brief

A clinical study evaluating Corticosteroid, Autologous Blood, and 1 other intervention for Lateral Epicondylitis and Comparing Autologous Blood Corticosteroid and Their Combined Injection for Treating Lateral Epicondylitis. Completed, enrolled 119 participants across 2 sites.

Detailed Summary

The goal of this clinical trial is to compare autologous blood, corticosteroid, and their combined injection for treating lateral epicondylitis. The main question it aims to answer are: • Which of these highly used drugs in treatment of lateral epicondylitis is more effective? Participants were randomly allocated into three equal treatment groups (AB versus CS versus their combination) with sealed envelopes prepared by a computer-based random number generator. Patients in the AB Group received 1 ml of autologous venous blood mixed with 2 ml of 2% prilocaine HCl, patients in the CS Group received 1 ml of 40 mg methylprednisolone acetate mixed with 2 ml of 2% prilocaine HCl, and patients in the Combined Group (AB+CS) received 1 ml of autologous venous blood, 1 ml of 40 mg methylprednisolone acetate mixed with 1 ml of 2% prilocaine HCl. Each group received an equal amount of (3 ml) injected material. PRTEE and HGS measurements were assessed before the injection (baseline values), on Day 15, Day 30, and Day 90, in the same manner by the senior author.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesTurkey (Türkiye)
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedFeb 1, 2024
Enrollment StartJan 1, 2023
Primary CompletionOct 30, 2023
Study CompletionNov 30, 2023
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 2.4 years ago

Interventions

Corticosteroiddrug

1 ml of 40 mg methylprednisolone acetate

Autologous Blooddrug

1 ml of autologous venous blood

Local Anestheticdrug

1 ml of 2% prilocaine HCl